| Alzheimer's disease JAS Lopez, HM González, GC Léger Handbook of clinical neurology 167, 231-255, 2019 | 623 | 2019 |
| Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia M Mesulam, A Wicklund, N Johnson, E Rogalski, GC Léger, A Rademaker, ... Annals of Neurology: Official Journal of the American Neurological …, 2008 | 573 | 2008 |
| Dopa decarboxylase activity of the living human brain. A Gjedde, J Reith, S Dyve, G Leger, M Guttman, M Diksic, A Evans, ... Proceedings of the National Academy of Sciences 88 (7), 2721-2725, 1991 | 203 | 1991 |
| Pharmacological treatment of Alzheimer disease F Massoud, GC Léger The Canadian Journal of Psychiatry 56 (10), 579-588, 2011 | 146 | 2011 |
| 6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods H Hoshi, H Kuwabara, G Léger, P Cumming, M Guttman, A Gjedde Journal of Cerebral Blood Flow & Metabolism 13 (1), 57-69, 1993 | 120 | 1993 |
| Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to … H Kuwabara, P Cumming, J Reith, G Leger, M Diksic, AC Evans, ... Journal of Cerebral Blood Flow & Metabolism 13 (1), 43-56, 1993 | 120 | 1993 |
| Striatal L‐dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis A Gjedde, GC Léger, P Cumming, Y Yasuhara, AC Evans, M Guttman, ... Journal of neurochemistry 61 (4), 1538-1541, 1993 | 94 | 1993 |
| Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans P Cumming, GC Léger, H Kuwabara, A Gjedde Journal of Cerebral Blood Flow & Metabolism 13 (4), 668-675, 1993 | 89 | 1993 |
| Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3 … DK Burns, RC Alexander, KA Welsh-Bohmer, M Culp, C Chiang, J O’Neil, ... The Lancet Neurology 20 (7), 537-547, 2021 | 67 | 2021 |
| Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease H Kuwabara, P Cumming, Y Yasuhara, GC Léger, M Guttman, M Diksic, ... Journal of Nuclear Medicine 36 (7), 1226-1231, 1995 | 60 | 1995 |
| Comparing the electronic and standard versions of the Montreal Cognitive Assessment in an outpatient memory disorders clinic: a validation study JL Berg, J Durant, GC Léger, JL Cummings, Z Nasreddine, JB Miller Journal of Alzheimer's Disease 62 (1), 93-97, 2018 | 52 | 2018 |
| Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia GC Léger, SJ Banks Dementia and geriatric cognitive disorders 37 (1-2), 104-112, 2014 | 52 | 2014 |
| Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa M Guttman, G Leger, A Reches, A Evans, H Kuwabara, JM Cedarbaum, ... Movement disorders: official journal of the Movement Disorder Society 8 (3 …, 1993 | 52 | 1993 |
| 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain M Guttman, G Léger, JM Cedarbaum, A Reches, W Woodward, A Evans, ... Annals of Neurology: Official Journal of the American Neurological …, 1992 | 49 | 1992 |
| Correction for partial volume effects in PET using MRI-based 3-D simulations of individual human brain metabolism OG Rousset, Y Ma, GC Leger, AH Gjedde, AC Evans Annals of Nuclear Medicine 7 (SUPPL. 1), S31-S32, 1993 | 47 | 1993 |
| Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson … JM Cedarbaum, G Leger, M Guttman Clinical neuropharmacology 14 (4), 330-342, 1991 | 46 | 1991 |
| Structural and functional MRI differences in master sommeliers: a pilot study on expertise in the brain SJ Banks, KR Sreenivasan, DM Weintraub, D Baldock, M Noback, ... Frontiers in Human Neuroscience 10, 414, 2016 | 41 | 2016 |
| Toward a revision of criteria for the dementias K Rockwood, RW Bouchard, R Camicioli, G Léger Alzheimer's & Dementia 3 (4), 428-440, 2007 | 40 | 2007 |
| Relationship between the activities of daily living questionnaire and the montreal cognitive assessment J Durant, GC Leger, SJ Banks, JB Miller Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 4, 43-46, 2016 | 37 | 2016 |
| Alzheimer's disease. SL JA, HM González, GC Léger Handbook of clinical neurology 167, 231-255, 2019 | 32 | 2019 |
Mark GuttmanCentre for Movement DisordersVerified email at movementdisorders.ca
